Parnassus Investments LLC Sells 15,575 Shares of IQVIA Holdings Inc. $IQV

Parnassus Investments LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 7.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 183,977 shares of the medical research company’s stock after selling 15,575 shares during the quarter. Parnassus Investments LLC’s holdings in IQVIA were worth $41,470,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Eubel Brady & Suttman Asset Management Inc. acquired a new stake in IQVIA in the third quarter worth about $14,278,000. Eagle Rock Investment Company LLC increased its position in IQVIA by 33.6% in the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after purchasing an additional 11,657 shares during the period. EDENTREE ASSET MANAGEMENT Ltd acquired a new stake in IQVIA in the third quarter worth about $7,368,000. AMG National Trust Bank acquired a new stake in IQVIA in the third quarter worth about $3,713,000. Finally, Cornerstone Investment Partners LLC grew its position in shares of IQVIA by 21.9% during the 3rd quarter. Cornerstone Investment Partners LLC now owns 344,103 shares of the medical research company’s stock worth $65,359,000 after buying an additional 61,725 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 0.7%

Shares of IQVIA stock opened at $180.89 on Friday. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04. The stock has a market cap of $30.19 billion, a P/E ratio of 22.41, a P/E/G ratio of 1.56 and a beta of 1.21. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business’s 50 day moving average is $173.39 and its 200-day moving average is $193.77.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IQV. Mizuho set a $215.00 target price on IQVIA in a research report on Monday, February 23rd. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a research report on Friday, March 6th. Morgan Stanley set a $225.00 price objective on IQVIA in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada assumed coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Buy” and a consensus price target of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.